Here’s a look at what the Trump administration’s decision to cut overhead funding for biomedical research means for ...
The No. 2 in command at the National Institutes of Health, Dr. Lawrence A. Tabak, who served as acting director of the agency ...
The FDA approved brentuximab vedotin (Adcetris) in combination with lenalidomide (Revlimid) and rituximab for relapsed or ...
A top-ranking scientist at the National Institutes of Health, Dr. Lawrence Tabak, was forced to retire this week, multiple ...
T he U.S. National Institutes of Health (NIH) is the largest funder of biomedical research in the world, and its grants ...
After the National Institutes of Health issued an order Friday night that would dramatically reduce funding, professor ...
The 80-year-old partnership between the federal government and research institutions has made the U.S. the leader in ...
The Trump administration’s NIH cuts may have been the result of a haphazard slash-and-burn strategy. But it can’t be ignored ...
The National Institutes of Health’s indirect funding cap could halt studies and limit researchers’ ability to find cures for ...
We’re talking about massive layoffs across the Triangle if this (rule) holds,” former UNC-Chapel Hill Chancellor Holden Thorp ...
The order was temporarily blocked after Massachusetts and 21 other states filed a lawsuit opposing the NIH funding cuts.
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback